

References

Al Sawah, S. et al., 2015. Effect of Corticosteroid Use by Dose on the Risk of Developing Organ Damage Over Time in Systemic Lupus Erythematosus-the Hopkins Lupus Cohort. *Lupus Science and Medicine*, 2(1).

Al-Herz, A., Ensworth, S., Shojania, K. & Esdaile, J., 2003. Cardiovascular Risk Factor Screening in Systemic Lupus Erythematosus. *Journal of Rheumatology*, 30(3), pp. 493-496.

Al-Kushi, G. et al., 2018. Effect of Vitamin D and Calcium Supplementation in Patients with Systemic Lupus Erythematosus. *Saudi journal of medicine & medical sciences*, 3(6), pp. 137-142.

Andrade, F., Casciola-Rosen, L. & Rosen, A., 2000. Apoptosis in Systemic Lupus Erythematosus. Clinical Implications. *Rheumatologic Disease Clinic of North America*, 26(2), pp. 215-227.

Andree, K. et al., 2017. Hypertension in Systemic Lupus Erythematosus Patient at Karawaci, Tangerang, Banten, Indonesia. *Journal of Hypertension*, 35(2).

Anić, F., Zuvčić-Butorac, M., Stimac, D. & Novak, S., 2014. New classification criteria for systemic lupus erythematosus correlate with disease activity. *Croatian medical journal*, 55(5), pp. 514-519.

Baqi, N. et al., 1996. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.. *J Am Soc Nephrol*, 7(6), pp. 924-929.

Beevers, G., Lip, Y. & O'Brien, E., 2001. ABC of hypertension: The pathophysiology of hypertension. *BMJ*, 322(7291), pp. 912-916.

Boyer, S., Templin, W. & Lanier, P., 1991. Rheumatic diseases in Alaskan Indians of the southeast coast: high prevalence of rheumatoid arthritis and systemic lupus erythematosus. *J Rheumatol*, Volume 18, pp. 1477-84.

Choi, J., Kim, S. & J, C., 2012. The pathogenesis of systemic lupus erythematosus-an update. *Current Opinion in Immunology*, 24(6), pp. 651-657.

Clancy, R., 2000. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. *Current Rheumatology Reports*, 2(1), pp. 39-43.

Cojocar, M., Cojocar, I., Silosi, I. & Vrabie, D., 2011. Manifestations of systemic lupus erythematosus. *Maedica*, 6(4), pp. 330-336.

Costedoat-Chalumeau, N. et al., 2013. Adherence to Treatment in Systemic Lupus Erythematosus Patients. *Best Practice and Research. Clinical Rheumatology*, 27(3), pp. 329-340.

Cross, J. & Benton, H., 1999. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus.. *Inflammation Research*, 48(5), p. 255–261.

Fairley, A. & Mathis, K., 2017. Cholinergic Agonists Reduce Blood Pressure in A Mouse Model of Systemic Lupus Erythematosus. *Physiological Report*, 5(8).

Falkner, B. et al., 2006. The relationship of body mass index and blood pressure in primary care pediatric atients. *Journal of Pediatrics*, 148(2), p. 195–200.

Fang, H., Ahmad, R., Magder, L. & Petri, M., 2012. *Lack of Control of Hypertension in Systemic Lupus Erythematosus*. Washington D.C., 2012 ACR/ARHP Annual Meeting.

Flynn, J. et al., 2017. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*, 140(3).

Guo, Q. et al., 2010. Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases. *Clin Rheumatol* 29, Volume 29, p. 1175–1180.

Hargraves, M., Richmond, H. & Morton, R., 1948. Presentation of two bone marrow components, the tart cell and the LE cell. *Mayo Clin Proc*, Volume 23, pp. 25-28.

Harrison, D. et al., 2011. Inflammation, immunity and hypertension. *Hypertension*, 57(2), pp. 132-140.

Harrison, D., Vinh, A., Lob, H. & M. M., 2010. Role of the adaptive immune system in hypertension. *Curr Opin Pharmacol*, 10(2), pp. 203-207.

Hrycek, E. et al., 2017. *Accelerated Atherosclerosis in Patients with Systemic Lupus Erythematosus and the Role of Selected Adipocytokines in This Process*. [Online] [Accessed 17 May 2019].

Jang, Y. & Stollar, B., 2003. Anti-DNA Antibodies: Aspects of Structure and Pathogenicity. *Cellular and Molecular Life Science*, 60(2), pp. 309-320.

Levy, D. & Kamphuis, S., 2012. Systemic lupus erythematosus in children and adolescents. *Pediatric clinics of North America*, 59(2), p. 345–364.

Listiyono, F., Murni, I., Sumadiono, S. & Satria, C., 2019. Predictors of mortality in children with systemic lupus erythematosus. *Paediatrica Indonesiana*, 59(1).

Manzi, S. et al., 1997. Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. *American Journal of Epidemiology*, 145(5), pp. 408-415.

Mikdashi, J. & Nived, O., 2015. Measuring Disease Activity in Adults with Systemic Lupus Erythematosus: the Challenges of Administrative Burden and Responsiveness to Patient Concerns in Clinical Research. *Arthritis Research & Therapy*, 17(1), p. 183.

Parks, C. & De Roos, A., 2014. Pesticides, Chemical and Industrial Exposures in Relation to Systemic Lupus Erythematosus. *Lupus*, 23(6), pp. 527-536.

- Paut, K., Piram, M., Guillaume, S. & Tran, T., 2007. Lupus in Adolescence. *Lupus*, 16(1), pp. 606-612.
- Piper, M. et al., 2007. Impaired Endothelial Function in Systemic Lupus Erythematosus. *Lupus*, 16(2), p. 84–88.
- Pons-Estel, J. et al., 2010. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. *Seminars in Arthritis and Rheumatism*, 39(4), pp. 257-268.
- Rahman, S., 2012. Systemic Lupus Erythematosus in Children: An Update. *Bangladesh Journal of Child Health*, 36(1), pp. 1-10..
- Ripley, B. et al., 2005. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. *Annals of the Rheumatic Diseases*, 64(6), pp. 849-853.
- Ruper, J. et al., 2012. Systematic Review of the Epidemiology of Systemic Lupus Erythematosus in the Asia-Pacific Region: Prevalence, Incidence, Clinical Features, and Mortality. *Arthritis Care and Research*, 64(2), pp. 159-168.
- Sabio, J. et al., 2011. Prevalence of and Factors Associated with Hypertension in Young and Old Women with Systemic Lupus Erythematosus. *The Journal of Rheumatology*, 38(6), pp. 1026-1032.
- Shaharir, S. et al., 2015. Persistent Hypertension in Lupus Nephritis and the Associated Risk Factors. *Clinical Rheumatology*, 34(2), pp. 93-97.
- Taylor, E. & Ryan, M., 2017. Understanding mechanisms of hypertension in systemic lupus erythematosus. *Therapeutic Advances in Cardiovascular Disease*, 11(1), pp. 20-32.
- Thamer, M. et al., 2009. Prednisone, Lupus Activity, and Permanent Organ Damage. *The Journal of Rheumatology*, 36(3), p. 560–564.
- Whelton, P. et al., 2018. The 2017 American College of Cardiology/American Heart Association Clinical Practice Guideline for High Blood Pressure in Adults. *Journal of the American College of Cardiology*, 3(4), pp. 127-248.
- Yasir, M. & Sonthalia, S., 2019. *Corticosteroid Adverse Effects*. Treasure Island: Stat Pearls.
- Zhang, W. et al., 2012. Interleukin 6 Underlies Angiotensin II-induced Hypertension and Chronic Renal Damage. *Hypertension*, 59(1), p. 136–144.